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The extracellular domain of the epidermal growth fac-
tor (EGF) receptor (EGFR) comprises four subdomains
(I–IV) and mediates binding of several different
polypeptide ligands, including EGF, transforming
growth factor-a, and heparin-binding EGF. Previous
studies have predominantly implicated subdomain III in
ligand binding. To investigate a possible role for se-
quences in subdomain IV, we constructed several mu-
tant EGFRs in which clusters of charged or aromatic
amino acids were replaced with alanine. Analysis of sta-
bly transfected Chinese hamster ovary cells expressing
mutant EGFRs confirmed that they were present on the
cell surface at levels approaching that of the wild-type
receptor. Although tyrosine phosphorylation of most
mutants was markedly induced by EGF, a cluster muta-
tion (mt25) containing four alanine substitutions in the
span of residues 521–527 failed to respond. EGF-induced
tyrosine phosphorylation of an alternative mutant
(DEN) with amino acids 518–589 deleted was also greatly
diminished. Larger doses of EGF or heparin-binding
EGF induced only weak tyrosine phosphorylation of
mt25, whereas the response to transforming growth fac-
tor-a was undetectable. These results suggest that mt25
might be defective with respect to either ligand binding
or receptor dimerization. Quantitative analyses showed
that binding of 125I-EGF to mt25 and DEN was reduced to
near background levels, whereas binding of EGF to
other cluster mutants was reduced 60–70% compared
with wild-type levels. Among the mutants, only mt25 and
DEN failed to form homodimers or to transphosphory-
late HER2/Neu in response to EGF treatment. Collec-
tively, our results are the first to provide direct evidence
that discrete subdomain IV residues are required for
normal binding of EGF family ligands. Significantly,
they were obtained with the full-length receptor in vivo,
rather than a soluble truncated receptor, which has
been frequently used for structure/function studies of
the EGFR extracellular region.
The epidermal growth factor (EGF)1 receptor (EGFR;
ErbB1), a large transmembrane glycoprotein with ligand-in-
ducible tyrosine kinase activity, is a member of a conserved
receptor family that includes HER2/Neu/ErbB2, HER3/ErbB3,
and HER4/ErbB4 (1–3). Shared characteristics of ErbB recep-
tors include an extracellular (EC) region with two cysteine-rich
repeats, a single transmembrane domain, and a cytoplasmic
sequence containing a tyrosine kinase and autophosphoryla-
tion sites (4). ErbB receptors dimerize upon ligand binding (5,
6), and this is critical for conversion to the high affinity binding
state as well as for intermolecular receptor transphosphoryla-
tion (7, 8). Homodimers as well as various combinations of
heterodimers are formed, depending on the relative levels of
the four receptors as well as the activating ligand (9, 10).
Because ErbB receptors contain different phosphotyrosine mo-
tifs, heterodimerization is believed to expand potential signal-
ing diversity or intensity.
ErbB receptors are bound and activated by members of a
ligand superfamily characterized by a conserved, three-disul-
fide loop structure (the EGF-like motif) that is required for high
affinity receptor binding (Ref. 11; reviewed in Ref. 12). This
superfamily includes the EGF and neuregulin subfamilies. Be-
sides its namesake, the EGF subfamily includes transforming
growth factor-a (TGF-a), amphiregulin, heparin-binding EGF
(HB-EGF), betacellulin, and epiregulin. These ligands all bind
EGFR, although a subset also directly binds ErbB4 (10, 13, 14).
The second ligand family, the neuregulins, comprise a set of
isoforms derived from three distinct genes by alternative splic-
ing (15–18). Neuregulins bind and activate ErbB3 and ErbB4,
but not EGFR (16, 17, 19). No direct ErbB2-binding EGF or
neuregulin ligand has yet been identified. Instead, this recep-
tor might function as a preferred heterodimerization partner,
mediating activation of other ErbB proteins via sequential
interaction and transphosphorylation (9, 20). These complex
ligand/receptor interactions indicate that ErbB, EGF, and neu-
regulin proteins are most appropriately viewed as components
of an intricate, highly regulated signaling network.
The EC region of EGFR and other ErbB receptors is divided
into four subdomains. Subdomain I corresponds to the N ter-
minus, whereas subdomain III is flanked by subdomains II and
IV, the cysteine-rich repeats. Evidence to date indicates that
EGFR subdomains I and especially III are the major determi-
nants of ligand binding (21). Mutant EGFR proteins lacking
subdomain I (22) or containing insertional mutations in subdo-
main III (23) have markedly lower affinity for EGF and TGF-a.
Additionally, substitution of subdomain III of chicken EGFR
with that of human EGFR restores high affinity binding toward
murine EGF, characteristic of the human receptor (24, 25).
Finally, cyanogen bromide mapping has identified sequences in
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subdomain III that are cross-linked to ligand (26, 27) or recog-
nized by ligand-competitive antibodies (27, 28).
ErbB EC domains may also mediate receptor dimerization.
The EGFR EC domain forms ligand-dependent homodimers in
solution (7, 29, 30), and mutation or deletion of sequences in
the EC juxtamembrane region of HER2/Neu induces constitu-
tive receptor activation via inappropriate disulfide bonding (31,
32). Additionally, EC domain interactions are required for for-
mation of heterodimers of wild-type HER2/Neu and EGFR (3,
33, 34) that are signaling-competent (35). Despite their appar-
ent importance, EC domain sequences mediating receptor
dimerization have not been well defined. Moreover, the manner
in which binding of various ligands differentially regulates
ErbB receptor dimerization or underlies ligand-specific differ-
ences in bioactivity is also unclear.
To further define sequence motifs in the EGFR EC domain
that are involved in ligand binding and/or receptor dimeriza-
tion, we performed site-directed mutagenesis. In contrast to
most previous studies that manipulated soluble truncated re-
ceptor forms corresponding to the EC domain, we utilized full-
length EGFR and extended the analyses to examine HER2/Neu
transphosphorylation. Our initial focus was the potential role
of EGFR subdomain IV sequences in receptor homo- and het-
erodimerization. However, we were surprised to find that a
small cluster of mutations in subdomain IV dramatically im-
paired the binding of several EGFR ligands. Additionally, mu-
tation of other subdomain IV clusters also reduced ligand bind-
ing to 30–40% of control. Our results thus unexpectedly
implicated this portion of the extracellular domain in ligand/
receptor interactions.
EXPERIMENTAL PROCEDURES
Reagents—All restriction and modification enzymes were purchased
from New England Biolabs Inc. (Beverly, MA) unless otherwise noted.
R408 was from Promega (Madison, WI).
EGFR Construction and Mutagenesis—Full-length human EGFR
cDNA, kindly provided by Dr. Glenn Merlino (National Institutes of
Health, Bethesda, MD), was subcloned into pcDNA3 (Invitrogen, San
Diego, CA) to generate pc3-EGFR. The latter vector was used for both
mutagenesis and expression.
Charged-to-alanine mutagenesis (36, 37) of EGFR subdomain IV was
performed as described previously (38) using the Muta-Gene Phagemid







TTGTC-39; and pr27, 59-CAGGTGGCACACATGGCCGGCTGCT-
GCGTATGCTGCTGCCAGGGTGTTGTTTTTTTCTCCCAT-39.
To delete nucleotides 1810–2025 of subdomain IV, a NaeI restriction
site (nucleotide 2025) was converted to an EcoNI site using the primer
prDNaeI (59-TGGATGGCACAGGTGGCACACCTGAGCGAGGTCTGC-
GTACTTCCAGACCTACTTCCAGACCAG-39). All annealing reactions
also included a primer designed to eliminate a unique BstBI restriction
site present in the vector sequence (38), thus allowing for elimination of
WT templates. Second-strand synthesis products were passaged
through BMH cells (Promega) to inactivate the uracil templates, and
BstBI-resistant DNAs were amplified in DH5a cells (Life Technologies,
Inc.). The authenticity of wild-type or mutant sequences was confirmed
by automated DNA sequencing.
Isolation of EGFR Cell Clones—Chinese hamster ovary (CHO) cells
(American Type Culture Collection, Manassas, VA), cultured as de-
scribed previously (38), were transfected with EGFR expression vectors
using Dosper reagent (Roche Molecular Biochemicals). Geneticin (Life
Technologies, Inc.)-resistant clones were screened for surface expres-
sion of wild-type or mutant receptor proteins using an enzyme-linked
immunosorbent assay and a mixture of monoclonal antibodies specific
for the EC domain. Briefly, clones grown on gelatin-coated microtiter
plates were washed with PBS containing Ca21 and Mg21, fixed in 2%
Formalin and 0.04% glutaraldehyde for 5 min, washed with PBS/Ca21/
Mg21, and blocked in 3% BSA/PBS for 1 h. Fixed cells were then
incubated for 2 h with anti-EGFR monoclonal antibody (mAb) 1 1 mAb
3 (Lab Vision Corp., Fremont, CA) at 1:250 in 3% BSA/PBS. Plates were
washed, incubated with horseradish peroxidase-conjugated goat anti-
mouse IgG (Roche Molecular Biochemicals) at 1:2000 for 1 h, washed
again, and incubated with substrate solution. A405 nm values, measured
with a microplate reader, were normalized for cell density determined
by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide as-
say (Chemicon International, Inc., Temecula, CA). Results were con-
firmed by Western blotting. For some experiments, CHO cell clones
were transiently transfected with 100 ng of the full-length human
HER2 cDNA expression vector pLXSN-Neu (kindly provided by Dr.
David Stern, Yale University) (39) using LipofectAMINE (Life Technol-
ogies, Inc.).
Immunoprecipitation and Western Blot Analysis—To detect total
EGFR, subconfluent cells (60-mm dishes) were washed with PBS and
lysed in 500 ml of Triton X-100 lysis buffer (20 mM HEPES (pH 7.3), 150
mM NaCl, 1% Triton X-100, 2 mM EGTA, 2 mM EDTA, 2 mM sodium
orthovanadate, 50 mM sodium molybdate, 10 mM sodium fluoride, 1 mM
phenylmethylsulfonyl fluoride, 10 mg/ml leupeptin, and 10 mg/ml apro-
tinin). Lysates were centrifuged for 10 min at 14,000 rpm, and super-
natant protein concentrations were determined using the Bio-Rad pro-
tein assay. Samples (120–200 mg) were immunoprecipitated and
immunoblotted with anti-EGFR antibody ERCT (a gift from Dr. H.
Shelton Earp, University of North Carolina, Chapel Hill, NC) as de-
scribed previously (40).
To detect cell-surface EGFR, live cells were incubated with 5 mg/ml
EC domain-specific mAb 1 1 mAb 3 or mAb 11 (Lab Vision Corp.) for 2 h
in 3% BSA/PBS/Ca21/Mg21 at 4 °C. Washed cells were harvested in
Triton X-100 lysis buffer and centrifuged. Immunoprecipitates were
collected with protein G-agarose beads prior to Western blot analysis.
Ligand Stimulation—Subconfluent cells were serum-starved for
16–24 h in nonessential amino acids-supplemented DMEM and stim-
ulated for 2 min with human recombinant EGF (Upstate Biotechnology,
Inc., Lake Placid, NY), TGF-a, or HB-EGF (R&D Systems, Minneapolis,
MN). Cells were washed with PBS and lysed in Triton X-100 lysis
buffer, and EGFR was immunoprecipitated by incubating 350–500 mg
of protein sequentially with ERCT antibody and protein G-agarose.
Immune complexes were boiled in 100 ml of 23 SDS-polyacrylamide gel
electrophoresis sample buffer, and samples were resolved on duplicate
gels and transferred to polyvinylidene difluoride membranes. The mem-
branes were blocked with either 5% milk or 3% BSA in Tris-buffered
saline and 0.1% Tween 20 and probed with ERCT antibody or anti-
phosphotyrosine antibody RC20 (Transduction Laboratories, Lexing-
ton, KY), respectively.
Cells transiently transfected with pLXSN-Neu were serum-starved
36 h after LipofectAMINE treatment and 12–16 h later stimulated with
20 ng/ml EGF for 2 min. Receptors were immunoprecipitated with
either ERCT antibody or 5 mg/ml anti-HER2/Neu mAb 1 as described
above. Immune complexes were boiled in 30 ml of 23 SDS-polyacryl-
amide gel electrophoresis sample buffer and analyzed by Western blot-
ting using RC20 antibody. Blots were then stripped in 5 mM glycine and
15 mM HCl (40); washed with Tris-buffered saline and 0.1% Tween 20;
and blotted with anti-EGFR antibody 1005 or anti-HER2/Neu antibody
C-18 (both from Santa Cruz Biotechnology, Santa Cruz, CA),
respectively.
EGF Binding Assay—Subconfluent cells in 12-well plates were incu-
bated in triplicate with 15 mCi/ml (20 ng/ml) 125I-EGF (ICN Pharma-
ceuticals, Irvine, CA) in DMEM, 0.1% BSA, and 20 mM HEPES (DMEM/
BSA/HEPES) for 2 h at 4 °C. Duplicate wells were incubated with a
1000–2000-fold excess of unlabeled EGF to measure nonspecific bind-
ing. Wells were washed three times with PBS and solubilized in 0.5 ml
of 1 N NaOH, and equal portions were used to measure bound radioac-
tivity and protein concentration. Protein was trichloroacetic acid-pre-
cipitated, resuspended in 12.5 ml of 1 N NaOH, neutralized with 12.5 ml
of 1 N HCl, and assayed. To correct for cell-surface receptor expression,
duplicate plates were also incubated with 5 mg/ml anti-EGFR mAb 1 1
mAb 3 or mAb 11 in DMEM/BSA/HEPES for 2 h at 4 °C. They were
then washed, and 0.5 mCi/well 125I-protein A (ICN Pharmaceuticals)
was added for 1 h. Some wells were incubated without antibody to
correct for nonspecific binding of protein A. Cells were washed and
processed for radioactive counting and protein determination as de-
scribed above.
Dimerization Assay—Subconfluent cells grown in 100-mm dishes
were serum-starved, incubated with or without 200 ng/ml EGF in
DMEM/BSA/HEPES for 2 h at 4 °C, washed, and incubated with 5 mM
bis(sulfosuccinimidyl) suberate (Pierce) for 2 h at 4 °C. Cross-linking
was quenched by incubation in 20 mM Tris (pH 7.5) for 15 min at room
temperature. Cells were washed, harvested in radioimmune precipita-
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tion assay buffer (10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 25 mM KCl,
5 mM MgCl2, 2 mM EDTA, 5 mM EGTA, 1% Nonidet P-40, 0.1% SDS, and
1% sodium deoxycholate with 2 mM sodium orthovanadate, 50 mM
sodium molybdate, 10 mM sodium fluoride, 1 mM phenylmethylsulfonyl
fluoride, 10 mg/ml leupeptin, and 10 mg/ml aprotinin), and centrifuged
to remove debris. Lysate samples (500–800 mg) in 1 ml of buffer were
immunoprecipitated with ERCT antibody for 5 h at 4 °C, with protein
G-agarose beads added during the last 2 h. Immune complexes were
washed as described (41), resolved on 5% SDS-polyacrylamide gels, and
transferred to polyvinylidene difluoride membranes. The membranes
were blocked and probed for EGFR monomers and dimers using ERCT
antibody.
RESULTS
EGFR Mutagenesis—We replaced selected clusters of
charged or aromatic amino acids with alanine residues
throughout the EC region, focusing particularly on sequences
previously implicated in ligand binding or exhibiting signifi-
cant homology among ErbB family members. For each of ;20
clusters, 3–5 charged or aromatic residues were simulta-
neously replaced with alanine in a full-length human EGFR
cDNA using the method of Kunkel (42). Cytomegalovirus-di-
rected expression vectors containing mutant or WT EGFR pro-
teins or no insert were then transfected into CHO cells, and
Geneticin-resistant colonies were selected. Colonies were
screened for cell-surface receptor expression via an enzyme-
linked immunosorbent assay using a mixture of mAb 1 1 mAb
3 monoclonal antibodies, specific for the EGFR extracellular
domain.
Cell-surface expression of mutant EGFR proteins containing
alanine substitutions in subdomains I–III was low to undetect-
able by enzyme-linked immunosorbent assay. Similarly, Harte
and Gentry (23) reported that soluble receptors containing
insertional mutations in subdomain III are not efficiently se-
creted and that insertions in other subdomains markedly re-
duce receptor expression. Hence, we focused on six subdomain
IV mutants (Fig. 1) that were readily detected on the cell
surface (see below). In mt23, Arg-497 was mutated to alanine;
spontaneous mutation of this residue to lysine in a carcinoma
cell line results in reduced binding of TGF-a (43). With mt24–
mt27, clusters of 3–5 amino acids spanning EGFR residues
507–589 were, in each case, replaced with alanine. The DEN
mutant contained an in-frame deletion of amino acids 518–589
that encompassed mt25–mt27 (Fig. 1). A subdomain IV dele-
tion mutant lacking adjacent upstream sequence (amino acids
495–519) was not detectably expressed. Additionally, a mutant
containing several alanine substitutions surrounding Arg-497
was also not detectably expressed.
Expression of Mutant EGFR Proteins—Fig. 2 shows Western
blot analysis of representative CHO cell clones expressing WT
EGFR or EGFR subdomain IV mutants. Total EGFR was de-
tected by blotting immunoprecipitated receptor with an anti-
body (ERCT) directed against its C-terminal sequences. Cell-
surface EGFR was identified by incubating live cells with
monoclonal antibodies to the receptor’s EC domain (mAb 1 1
mAb 3 or mAb 11). Cells were then lysed, and protein G-
agarose-precipitated immune complexes were blotted with
ERCT antibody.
As expected, WT EGFR was predominantly detected as a
diffuse band of ;170 kDa corresponding to fully glycosylated,
surface-localized EGFR (Fig. 2, upper panel). Mutant EGFR
proteins were instead typically present in two forms: the broad
170-kDa band and a discrete band of 160 kDa that likely
corresponds to nascent EGFR still retained in intracellular
membranes (44, 45). The ratio of 170/160-kDa forms varied
with different mutants and was highest in the case of the
single-point mutant mt23. The deletion mutant DEN was pre-
dictably smaller and detected as both diffuse 160- and discrete
120-kDa bands. For all mutants, similar receptor profiles were
detected using multiple cell clones and an alternative anti-C
terminus antibody. Incubation of live cells with either mAb 1 1
mAb 3 or mAb 11 confirmed cell-surface localization of the
diffuse 170- or 160-kDa (DEN) receptor bands. The latter anal-
yses confirmed roughly comparable cell-surface expression of
wild-type and mutant EGFR proteins.
EGF-induced Tyrosine Phosphorylation—To assess whether
subdomain IV mutations affected EGF-induced tyrosine phos-
phorylation, serum-starved cells were stimulated for 2 min
with 10 ng/ml EGF. EGFR proteins were then immunoprecipi-
tated with ERCT antibody and immunoblotted with anti-phos-
photyrosine antibody RC20. To compare the levels of the vari-
ous EGFR proteins, blots were reprobed (or in some cases,
parallel blots were probed) with anti-receptor antibodies. As
shown in Fig. 3 (upper panel), EGF treatment rapidly induced
tyrosine phosphorylation of WT EGFR as well as the 170-kDa
surface form of mt23, mt24, mt26, and mt27. Interestingly,
basal phosphorylation of mt24 was observed in the absence of
EGF, but was not seen with the WT receptor. Most striking,
FIG. 1. Diagrammatic representation of EGFR and subdomain IV mutagenesis. Upper panel, the domain structure of EGFR showing EC
region subdomains I–IV, the transmembrane domain (TM), the tyrosine kinase sequence (TK), and the cytoplasmic tail (CT); lower panel,
mutagenesis of subdomain IV. Residues mutated to alanine are in boldface and italicized, denoted with overhead dots, and numbered from the
receptor’s N terminus. DEN indicates a deletion mutant from which an EcoNI-NaeI fragment corresponding to the C-terminal portion of subdomain
IV (residues 518–589) has been removed.
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however, were the complete absence of EGF-induced tyrosine
phosphorylation of mt25 and the greatly reduced phosphoryl-
ation of DEN.
Focusing on selected mutants, we examined tyrosine phos-
phorylation in response to a higher dose of EGF (100 ng/ml),
and we examined the effects of equivalent concentrations of
TGF-a or HB-EGF (all human recombinant) as well. Fig. 4
shows that all three human ligands induced a marked increase
in the phosphotyrosine content of WT, mt24, and mt27 receptor
proteins, with HB-EGF and TGF-a eliciting the strongest and
weakest responses, respectively. In contrast, ligand-induced
tyrosine phosphorylation of mt26 and especially mt25 was dra-
matically reduced. Even at this high dose, mt25 was only
weakly phosphorylated in response to HB-EGF and EGF and
was unresponsive to TGF-a.
EGF Binding to WT and Mutant EGFR Proteins—The lack of
induced tyrosine phosphorylation of mt25 could result from
impaired binding of ligand to this mutant, although only EC
subdomains I and III have been clearly implicated in ligand/
receptor interactions. To address the contribution of subdo-
main IV, we assessed the binding of 125I-EGF to CHO cell
clones expressing WT or mutant EGFR proteins (Fig. 5, upper
panel). To normalize the results, we then compared the cell-
surface expression of the various receptor proteins by meas-
uring the binding of either mAb 1 1 mAb 3 or mAb 11 to live
cells as detected by 125I-protein A (Fig. 5, middle panel). Fig. 5
shows that a CHO cell clone expressing 5–6-fold lower levels of
cell-surface WT EGFR (wt-lo) than the WT clone previously
analyzed (wt-hi) bound comparably less 125I-EGF. Thus, when
normalized for cell-surface EGFR levels, the two clones dis-
played virtually identical binding activity (Fig. 5, lower panel).
Comparing the various mutants, only mt23 (the single-point
mutant) bound normalized levels of 125I-EGF that were iden-
tical to those of WT EGFR. This is consistent with the fact that
mt23 also displayed normal levels of receptor activation. In
contrast, normalized binding to mt24, mt26, and mt27 was
reduced to 30–40% of WT receptor levels. Most important,
however, binding of 125I-EGF to the unresponsive mt25 and
DEN receptors was reduced to near background levels. These
results indicate that subdomain IV sequences in the region
from amino acids 507 to 589 influence ligand binding, with
residues altered in mt25 having the greatest effect.
Dimerization of WT and Mutant EGFRs and Transphospho-
rylation of HER2/Neu—Since subdomain IV of ErbB proteins
has been implicated in receptor dimerization (32), we compared
the ability of WT and selected mutant receptors to dimerize
following EGF treatment. Cells were exposed to 200 ng/ml EGF
for 2 h, and receptor oligomers were stabilized using bis(sulfo-
succinimidyl) suberate, a noncleavable cross-linking reagent
(46). Cells were then lysed, and receptor complexes were im-
munoprecipitated with ERCT antibody. Western blotting of the
immunoprecipitateswithERCTantibodyreadilydetectedligand-
dependent dimers of WT EGFR and mt27 (Fig. 6), with dimers
of mt23 and mt24 also observed (data not shown). Consistent
with its reduced cell-surface expression and EGF binding, mt26
showed detectable but diminished ligand-induced dimeriza-
tion. In contrast, dimerization of mt25 was undetectable,
whereas a low basal level of DEN dimerization was not en-
hanced by ligand treatment.
For a more sensitive, functional dimerization assay, we ex-
amined the ability of WT and mutant receptors to transphos-
phorylate HER2/Neu in an EGF-dependent manner. Stable WT
and mutant clones were transiently transfected with low levels
of pLXSN-Neu (39) and 48 h later treated with 20 ng/ml EGF
for 2 min. The respective ErbB receptors were then immuno-
precipitated with ERCT antibody or anti-HER2/Neu mAb 1,
and the levels of receptor phosphotyrosine and protein were
compared by Western blotting. Consistent with previous re-
sults, EGF treatment induced marked tyrosine phosphoryla-
tion of WT, mt23, mt24, and mt27 EGFR proteins and lower
phosphorylation of mt26, but failed to induce phosphorylation
of mt25 and DEN.
HER2/Neu displayed basal phosphorylation in most cell pop-
ulations, with the exception of the DEN and vector clones,
which showed lower HER2 expression. This basal phosphoryl-
ation (typical in transient transfectants with high levels of
expression) was nevertheless increased by EGF in cells stably
expressing WT EGFR or most mutant receptors. In contrast,
EGF-induced phosphorylation of HER2 was not observed with
mt25 and DEN. These results are consistent with the EGFR
activation profile and further indicate that none of the subdo-
main IV mutations inhibit EGFR homo- or heterodimerization
independent of effects on ligand binding.
DISCUSSION
Previous evidence predominantly implicated EGFR subdo-
main III, and especially its C-terminal portion, in ligand bind-
ing. CNBr mapping identified a single receptor fragment that
was cross-linked to iodinated EGF (26). Encompassing residues
294–543, this fragment spanned subdomain III and the N-
terminal portion of subdomain IV. In agreement, a slightly
smaller proteolytic fragment bound EGF or TGF-a with disso-
ciation constants similar to those of intact soluble EGFR (47).
More refined mapping of epitopes for EGF-competing antibod-
ies identified a continuous 14-amino acid sequence (residues
351–364) within subdomain III (28), and a 47-amino acid frag-
ment encompassing this epitope was cross-linked to EGF (27).
These physical analyses were corroborated by a functional as-
FIG. 2. Surface expression of wild-type and mutant EGFR pro-
teins. Total EGFR was immunoprecipitated (IP) from lysates of CHO
cell clones expressing WT or mutant proteins using ERCT antibody (Ab;
upper panel). Alternatively, live cells were incubated with EC domain
mAb 1 1 mAb 3 (middle panel) or mAb 11 (lower panel), and the
cell-surface receptor was immunoprecipitated and probed with ERCT
antibody. The approximate molecular masses of EGFR species are
indicated. vector denotes control CHO cells transfected with the paren-
tal pcDNA3 vector. Multiple clones were examined in each case, and
representative results are shown.
FIG. 3. EGF-induced tyrosine phosphorylation of wild-type
and mutant EGFR proteins. Subconfluent cells were treated with or
without 10 ng/ml EGF for 2 min and then washed, lysed, and immuno-
precipitated with ERCT antibody. Immunoprecipitates resolved on du-
plicate gels were probed with either anti-phosphotyrosine antibody
RC20 (upper panel; pTyr) or ERCT antibody (lower panel; EGFR).
Representative results of six experiments are shown.
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say in which subdomain III of chicken EGFR was replaced with
the corresponding region of the human receptor. In contrast to
human EGFR, the chicken receptor binds murine EGF with
100-fold reduced affinity. However, a chicken chimera that
contained subdomain III of human EGFR bound EGF in a
manner indistinguishable from that of the mammalian recep-
tor (24). Collectively, these results argue strongly that subdo-
main III contributes major ligand-binding determinants.
Although the involvement of subdomain III in ligand binding
has considerable support, other portions of the extracellular
region have also been implicated. Conservation of sequence
between subdomains I and III implies that the former might
contribute to ligand binding. Indeed, a mutant EGFR devoid of
subdomain I exhibited a 10-fold lower affinity for EGF com-
pared with the wild-type receptor (22). Subdomains II and IV
may also contribute to ligand/receptor interactions. Harte and
Gentry (23) reported that soluble EC domain receptors contain-
ing subdomain II insertions of 4–5 hydrophobic or charged
amino acids bound EGF normally, but not TGF-a. This finding
raised the possibility that the affected sites selectively regulate
the binding of different EGF family members. Moreover, two
mutants containing subdomain II or IV insertions at sites
equidistant from the center of subdomain III showed increased
ligand binding. Affinity was unaltered, leading the investiga-
tors to suggest that disruption of these sites promoted the
binding of more than one ligand molecule.
Additional evidence implicates subdomain IV or the follow-
ing juxtamembrane sequence. A naturally occurring R497K
mutant, first identified in human lymphocytes and several
cancer cell lines, displayed only low affinity binding of TGF-a,
but retained both high and low affinity binding of EGF (43).
(Surprisingly, the less conservative replacement of Arg-497
with alanine in the present study (mt23; Fig. 1) did not appre-
ciably affect the binding of either EGF or TGF-a, nor did it
affect receptor activation by these ligands.) On the other hand,
a more disruptive insertion of 23 amino acids in the EC jux-
tamembrane region reduced EGF binding, although receptor
dimerization was still observed (48).
Here, we provide the strongest evidence to date that residues
within EGFR subdomain IV influence interactions between the
receptor and its ligands. The deletion mutant DEN, which lacks
72 amino acids (positions 518–589) from the C-terminal half of
subdomain IV, but retains the juxtamembrane sequence,
bound little to no EGF. Furthermore, several mutant EGFR
proteins, each of which contained three to five alanine substi-
tutions in the subdomain region from amino acids 507 to 589,
all displayed 60–70% reductions in EGF binding compared
with the wild-type receptor. Most significantly, mt25, which
harbored only five charged/aromatic-to-alanine substitutions
in a 7-amino acid stretch in the middle of subdomain IV (and
was encompassed by the DEN deletion), bound dramatically
reduced levels of EGF, TGF-a, and HB-EGF. The latter was
particularly important since the DEN deletion is predicted to
leave unpaired cysteines at both the beginning and end of the
FIG. 4. Ligand-induced tyrosine phosphorylation of wild-type and mutant EGFR proteins. CHO clones expressing wild-type or mutant
receptors were treated with or without 100 ng/ml EGF (E), TGF-a (T), or HB-EGF (H) for 2 min, washed, and lysed. Samples immunoprecipitated
with ERCT antibody were analyzed as described in the legend to Fig. 3. Representative results of three experiments are shown. GF, growth factor.
FIG. 5. EGF binding to wild-type and mutant receptors. Upper
panel, CHO cell clones expressing either low or high levels of wild-type
EGFR or the indicated mutant receptors (e.g. 23 5 Mt23) were incu-
bated with 125I-EGF for 2 h, and samples were processed for counting as
described under “Experimental Procedures.” Nonspecific binding was
assessed in the presence of a 1000–2000-fold excess of unlabeled EGF.
Values (cpm/mg of protein) represent the average of triplicate determi-
nations. Middle panel, to quantitate cell-surface expression of EGFR
proteins, clones were incubated for 2 h with or without 5 mg/ml mAb 11
and then for 1 h with 125I-protein A and processed for counting. Values
(cpm/mg of protein) represent the average of triplicate samples. Lower
panel, shown is the ratio of bound EGF to cell-surface EGFR levels. V,
vector.
FIG. 6. Detection of EGF-induced EGFR homodimers. CHO cell
clones expressing wild-type or mutant receptors were treated for 2 h
with 200 ng/ml EGF, washed, and incubated with bis(sulfosuccinimidyl)
suberate cross-linker for 2 h. After quenching, lysates were prepared
and immunoprecipitated with anti-EGFR antibody. Immunoprecipi-
tates were resolved on 5% gels, blotted, and probed with ERCT
antibody.
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deletion (49, 50) and hence could dramatically affect the con-
formation of the EC region.
How the critical subdomain IV residues contribute to ligand
binding is unclear. Possibly, these residues directly contribute
to a ligand-binding pocket or instead participate in interactions
with subdomain III that indirectly affect the conformation of
the binding pocket. The latter possibility is consistent with
models of the EGFR EC region that predict that the four
subdomains comprise largely independent structures that in-
teract to form a binding site through EC domain folding (21).
Interestingly, alignment of subdomains II and IV relative to
cysteine residues reveals that the residues altered in mt25 fall
within a 14-amino acid sequence not represented (i.e. a gap) in
subdomain II (23). Thus, subdomain IV may contribute unique
motifs required for proper ligand/receptor interactions. Con-
sistent with this speculation, Summerfield et al. (51) mapped
the receptor site proximal to the C terminus of bound EGF to
the interface between subdomains III and IV.
An alternative explanation for our results, suggested by the
crystal structure of an insulin-like growth factor I receptor EC
domain fragment (50), is that the mt25 mutations might intro-
duce a negative influence on ligand binding. Thus, a critical
interaction between corresponding portions of that receptor’s
EC region appears to involve the insertion of a tryptophan
(Trp-492) from the cysteine-rich region (equivalent to EGFR
subdomain IV) into a hydrophobic core formed by the preceding
subdomain. Since EGFR contains an equivalent conserved
tryptophan, this residue may play a critical role in interactions
between EGFR subdomains III and IV. EGFR Trp-492 is lo-
cated ,30 amino acids upstream of the mt25 mutations, rais-
ing the possibility that even the limited alterations of mt25
constrain the ability of Trp-492 to interact with subdomain III.
This “negative influence” scenario may be consistent with find-
ings that subdomain III alone bound EGF and TGF-a with a Kd
indistinguishable from that of the soluble EGFR EC domain (6,
47). It may also be consistent with the modest, ligand-depend-
ent phosphorylation of the DEN mutant observed in Fig. 3. On
the other hand, the soluble EC domain has markedly reduced
affinity for ligands compared with the full-length receptor (41),
raising the possibility that the contributing role of mt25 se-
quences would not be apparent with EC domain fragments.
Interestingly, our mutational analysis did not identify resi-
dues that affect receptor dimerization without affecting ligand
binding. Thus, only mutants with negligible EGF binding failed
to homodimerize or transphosphorylate HER2/Neu in a ligand-
dependent manner. Nevertheless, a variety of evidence sup-
ports a role for subdomain IV in ErbB interactions. This in-
cludes the finding that a naturally occurring mutant EGFR
that is expressed in various human epithelial tumors and lacks
subdomains I and II heterodimerized with HER2/Neu (52).
Additionally, deletion of cysteines and surrounding residues
within subdomain IV of HER2/Neu resulted in constitutive
oligomerization of this ErbB receptor (32). Since we did not
perform saturation mutagenesis of subdomain IV, residues
critical for dimerization but not ligand binding may have been
missed. Alternatively, dimerization may depend on the contri-
bution of multiple motifs distributed throughout the extracel-
lular and intracellular regions of ErbB receptors. Clearly, fur-
ther studies of ErbB EC domains and their roles in ligand
binding and receptor homo- and heterodimerization are
warranted.
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